| 000 | 01747 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513151309.0 | ||
| 264 | 0 | _c19980908 | |
| 008 | 199809s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/S0140-6736(05)60466-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCréange, A | |
| 245 | 0 | 0 |
_aTreatment of Guillain-Barré syndrome with interferon-beta. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cAug 1998 |
||
| 300 |
_a368-9 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_aAction Potentials _xphysiology |
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xtherapeutic use |
| 650 | 0 | 4 |
_aAutonomic Nervous System Diseases _xphysiopathology |
| 650 | 0 | 4 | _aCampylobacter Infections |
| 650 | 0 | 4 | _aCampylobacter jejuni |
| 650 | 0 | 4 |
_aCranial Nerve Diseases _xphysiopathology |
| 650 | 0 | 4 |
_aCytokines _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunity, Cellular _ximmunology |
| 650 | 0 | 4 |
_aInflammation Mediators _ximmunology |
| 650 | 0 | 4 |
_aInterferon-beta _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscle Weakness _xphysiopathology |
| 650 | 0 | 4 |
_aNeural Conduction _xphysiology |
| 650 | 0 | 4 |
_aParesis _xphysiopathology |
| 650 | 0 | 4 |
_aPeripheral Nervous System Diseases _xphysiopathology |
| 650 | 0 | 4 |
_aPolyradiculoneuropathy _ximmunology |
| 650 | 0 | 4 | _aReflex, Abnormal |
| 650 | 0 | 4 |
_aSensation Disorders _xphysiopathology |
| 700 | 1 | _aLerat, H | |
| 700 | 1 | _aMeyrignac, C | |
| 700 | 1 | _aDegos, J D | |
| 700 | 1 | _aGherardi, R K | |
| 700 | 1 | _aCesaro, P | |
| 773 | 0 |
_tLancet (London, England) _gvol. 352 _gno. 9125 _gp. 368-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(05)60466-7 _zAvailable from publisher's website |
| 999 |
_c9683365 _d9683365 |
||